BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1182 related articles for article (PubMed ID: 18707819)

  • 41. Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study.
    Low WK; Toh ST; Wee J; Fook-Chong SM; Wang DY
    J Clin Oncol; 2006 Apr; 24(12):1904-9. PubMed ID: 16622266
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluating the role of prophylactic gastrostomy tube placement prior to definitive chemoradiotherapy for head and neck cancer.
    Chen AM; Li BQ; Lau DH; Farwell DG; Luu Q; Stuart K; Newman K; Purdy JA; Vijayakumar S
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1026-32. PubMed ID: 20231073
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy.
    Haynes DS; O'Malley M; Cohen S; Watford K; Labadie RF
    Laryngoscope; 2007 Jan; 117(1):3-15. PubMed ID: 17202923
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Analysis of salivary flow and dose-volume modeling of complication incidence in patients with head-and-neck cancer receiving intensity-modulated radiotherapy.
    Marzi S; Iaccarino G; Pasciuti K; Soriani A; Benassi M; Arcangeli G; Giovinazzo G; Benassi M; Marucci L
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1252-9. PubMed ID: 19251097
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
    Stadler P; Putnik K; Kreimeyer T; Sprague LD; Koelbl O; Schäfer C
    BMC Cancer; 2006 Dec; 6():279. PubMed ID: 17150114
    [TBL] [Abstract][Full Text] [Related]  

  • 46. concomitant chemoradiotherapy with mitomycin C and cisplatin in advanced unresectable carcinoma of the head and neck: phase I-II clinical study.
    Strojan P; Karner K; Smid L; Soba E; Fajdiga I; Jancar B; Anicin A; Budihna M; Zakotnik B
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):365-72. PubMed ID: 18394816
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Factors predictive of local disease control after intra-arterial concomitant chemoradiation (RADPLAT).
    Robbins KT; Doweck I; Samant S; Vieira F; Kumar P
    Laryngoscope; 2004 Mar; 114(3):411-7. PubMed ID: 15091211
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dysphagia after chemoradiotherapy for head-and-neck squamous cell carcinoma: dose-effect relationships for the swallowing structures.
    Dirix P; Abbeel S; Vanstraelen B; Hermans R; Nuyts S
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):385-92. PubMed ID: 19553033
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of low-dose cisplatin-based chemo-irradiation in assessing hearing loss for locally advanced head and neck cancer.
    Liao XB; Yan SX
    Radiother Oncol; 2009 Feb; 90(2):282, author reply 282-3. PubMed ID: 19042049
    [No Abstract]   [Full Text] [Related]  

  • 50. Sensory neural hearing loss after concurrent cisplatin and radiation therapy for nasopharyngeal carcinoma.
    Oh YT; Kim CH; Choi JH; Kang SH; Chun M
    Radiother Oncol; 2004 Jul; 72(1):79-82. PubMed ID: 15236878
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.
    Allen AM; Czerminska M; Jänne PA; Sugarbaker DJ; Bueno R; Harris JR; Court L; Baldini EH
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):640-5. PubMed ID: 16751058
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Toxicity of two cisplatin-based radiochemotherapy regimens for the treatment of patients with stage III/IV head and neck cancer.
    Rades D; Fehlauer F; Sheikh-Sarraf M; Kazic N; Basic H; Poorter R; Hakim SG; Schild SE; Dunst J
    Head Neck; 2008 Feb; 30(2):235-41. PubMed ID: 17657790
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prediction of Hearing Loss Due to Cisplatin Chemoradiotherapy.
    Theunissen EA; Zuur CL; Józwiak K; Lopez-Yurda M; Hauptmann M; Rasch CR; van der Baan S; de Boer JP; Dreschler WA; Balm AJ
    JAMA Otolaryngol Head Neck Surg; 2015 Sep; 141(9):810-5. PubMed ID: 26291150
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Radiation dose to otologic structures during head and neck cancer radiation therapy.
    Ondrey FG; Greig JR; Herscher L
    Laryngoscope; 2000 Feb; 110(2 Pt 1):217-21. PubMed ID: 10680919
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of radiation technique, radiation fraction dose, and total cisplatin dose on hearing : Retrospective analysis of 29 medulloblastoma patients.
    Scobioala S; Parfitt R; Matulat P; Kittel C; Ebrahimi F; Wolters H; Am Zehnhoff-Dinnesen A; Eich HT
    Strahlenther Onkol; 2017 Nov; 193(11):910-920. PubMed ID: 28887665
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Three-dimensional conformal radiotherapy for locally advanced (Stage II and worse) head-and-neck cancer: dosimetric and clinical evaluation.
    Portaluri M; Fucilli FI; Castagna R; Bambace S; Pili G; Tramacere F; Russo D; Francavilla MC
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1036-43. PubMed ID: 16750321
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Frequency of esophageal stenosis after simultaneous modulated accelerated radiation therapy and chemotherapy for head and neck cancer.
    Lawson JD; Otto K; Grist W; Johnstone PA
    Am J Otolaryngol; 2008; 29(1):13-9. PubMed ID: 18061826
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Feasibility study of single agent Cisplatin and concurrent radiotherapy in Japanese patients with squamous cell carcinoma of the head and neck: preliminary results.
    Zenda S; Onozawa Y; Tahara M; Kawashima M; Shikama N; Sasaki S; Boku N
    Jpn J Clin Oncol; 2007 Oct; 37(10):725-9. PubMed ID: 17925299
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of adding concomitant chemotherapy to hyperfractionated accelerated radiotherapy for advanced head-and-neck squamous cell carcinoma.
    Nuyts S; Dirix P; Clement PM; Poorten VV; Delaere P; Schoenaers J; Hermans R; Van den Bogaert W
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1088-95. PubMed ID: 18707823
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Major late toxicities after conformal radiotherapy for nasopharyngeal carcinoma-patient- and treatment-related risk factors.
    Lee AW; Ng WT; Hung WM; Choi CW; Tung R; Ling YH; Cheng PT; Yau TK; Chang AT; Leung SK; Lee MC; Bentzen SM
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1121-8. PubMed ID: 18723296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 60.